<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Transjugular intrahepatic portosystemic shunts: Postprocedure care and complications</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Transjugular intrahepatic portosystemic shunts: Postprocedure care and complications</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Transjugular intrahepatic portosystemic shunts: Postprocedure care and complications</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arun J Sanyal, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jasmohan S Bajaj, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Felipe B Collares, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sanjiv Chopra, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Transjugular intrahepatic portosystemic shunt (TIPS) is an important therapeutic tool for patients with complications of portal hypertension (eg, variceal bleeding, refractory ascites). TIPS placement reduces elevated portal pressure by creating a low-resistance channel between the hepatic vein and an intrahepatic branch of the portal vein using angiographic techniques. The tract is kept patent by deployment of an expandable stent across it, thereby allowing blood to return to the systemic circulation. An advantage of TIPS is that it functions like a surgical side-to-side portacaval shunt but is a minimally invasive procedure. However, TIPS insertion can be associated with a number of complications (eg, hepatic encephalopathy [HE], liver failure).</p><p>This topic will review postprocedure patient care and complications related to TIPS placement. The indications, contraindications, and pre-TIPS evaluation are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1265.html" rel="external">"Overview of transjugular intrahepatic portosystemic shunts (TIPS)"</a>.)</p><p>The clinical manifestations and diagnosis of portal hypertension in adults are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/90896.html" rel="external">"Portal hypertension in adults"</a>.)</p><p>Management of patients with portal hypertension and acute variceal bleeding is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1254.html" rel="external">"Overview of the management of patients with variceal bleeding"</a> and  <a class="medical medical_review" href="/z/d/html/1260.html" rel="external">"Methods to achieve hemostasis in patients with acute variceal hemorrhage"</a>.)</p><p class="headingAnchor" id="H20523996"><span class="h1">PATIENT CARE AFTER TIPS</span></p><p class="headingAnchor" id="H2086638763"><span class="h2">Initial postprocedure care</span><span class="headingEndMark"> — </span>Initial postprocedure care consists of observation, laboratory studies, and imaging [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Observation – Patients are observed for a minimum of six hours after TIPS placement for signs or symptoms of bleeding (hypotension, tachycardia), hepatic encephalopathy (HE), cardiac dysfunction, or pulmonary hypertension (eg, dyspnea). TIPS creates a rapid increase in venous return to the heart and can unmask cardiac dysfunction or pulmonary hypertension. (See <a class="local">'Postprocedure complications'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory studies – We check laboratory studies (complete blood count, international normalized ratio, and liver biochemical and function tests) within 72 hours after TIPS placement or sooner if a complication such as acute liver failure is suspected. (See <a class="local">'Liver failure'</a> below and  <a class="medical medical_review" href="/z/d/html/3574.html" rel="external">"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1">A decrease in hemoglobin, typically &lt;3 g/dL, has been observed in some patients after TIPS and has been attributed to hemolysis [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Imaging – A baseline ultrasound with Doppler of the liver is performed three to seven days after TIPS insertion to confirm shunt patency. Follow-up surveillance ultrasound studies are performed at one-, three-, and six-month intervals thereafter [<a href="#rid3">3,4</a>]. If ultrasound findings suggest TIPS stenosis, angiogram with portosystemic venous pressure gradient measurement is performed. (See <a class="local">'Post-TIPS surveillance'</a> below and <a class="local">'TIPS dysfunction'</a> below.)</p><p></p><p class="headingAnchor" id="H1632594934"><span class="h2">Medication adjustments</span><span class="headingEndMark"> — </span>Published data to guide medication adjustments after TIPS are lacking. Our approach is based on clinical experience and depends on the indication for TIPS:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with variceal bleeding – For patients who had TIPS for control of active variceal bleeding, we typically continue pharmacologic therapy (ie, <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a>) for 24 to 48 hours and then discontinue it if no further bleeding occurs. (See  <a class="medical medical_review" href="/z/d/html/1260.html" rel="external">"Methods to achieve hemostasis in patients with acute variceal hemorrhage", section on 'Pharmacologic therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with refractory ascites – For patients who had TIPS for refractory ascites, we resume sodium restriction and initially continue the pre-TIPS diuretic regimen. Diuretics are slowly tapered over the next several months, provided that ascites does not reaccumulate [<a href="#rid5">5</a>]. Diuretic therapy for patients with ascites, including specific regimens and patient monitoring, is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1256.html" rel="external">"Ascites in adults with cirrhosis: Initial therapy", section on 'Diuretic therapy'</a>.)</p><p></p><p class="headingAnchor" id="H1715310386"><span class="h2">Post-TIPS surveillance</span><span class="headingEndMark"> — </span>To assess TIPS patency, we obtain liver ultrasound with Doppler study between three and six months after TIPS and then at six-month intervals for long-term surveillance. Of note, most patients with cirrhosis have a liver ultrasound every six months to screen for hepatocellular carcinoma. (See  <a class="medical medical_review" href="/z/d/html/3583.html" rel="external">"Surveillance for hepatocellular carcinoma in adults"</a>.)</p><p>The goal of surveillance is to detect TIPS stenosis before the patient develops recurrent symptoms of portal hypertension (eg, ascites), while data to support this practice are limited [<a href="#rid1">1,6-8</a>]. Detecting shunt stenosis prior to complete occlusion allows for early intervention, and treating shunt stenosis is typically more successful than treating shunt occlusion. (See <a class="local">'TIPS dysfunction'</a> below.)</p><p>If ultrasound findings suggest TIPS stenosis, we obtain an angiogram with portosystemic venous pressure gradient measurement to confirm the presence of shunt stenosis prior to TIPS revision. Portosystemic venous pressure gradient (PSG) measures the gradient in pressure between the portal vein and the systemic circulation (ie, inferior vena cava or right atrium), and if the PSG is ≥12 mmHg, patients are at risk for variceal bleeding and ascites. (See  <a class="medical medical_review" href="/z/d/html/90896.html" rel="external">"Portal hypertension in adults", section on 'Hepatic venous pressure gradient'</a>.)</p><p>Liver ultrasound with Doppler is the primary surveillance tool because it is noninvasive and widely available, and its accuracy is comparable to invasive methods (venography) [<a href="#rid9">9,10</a>]. In a study including 43 patients who had undergone TIPS, the sensitivity and specificity of liver ultrasound with Doppler study for detecting TIPS stenosis was 92 and 72 percent, respectively [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H237286866"><span class="h1">POSTPROCEDURE COMPLICATIONS</span></p><p class="headingAnchor" id="H280540287"><span class="h2">Issues related to portosystemic shunting</span></p><p class="headingAnchor" id="H2433156527"><span class="h3">Hepatic encephalopathy</span></p><p class="headingAnchor" id="H3101055607"><span class="h4">Incidence and etiology</span><span class="headingEndMark"> — </span>Hepatic encephalopathy ([HE], also referred to as portosystemic encephalopathy [PSE]) is a complication of TIPS due to shunting of blood from the portal to systemic circulation. The incidence of HE following TIPS ranges from 30 to 50 percent, and chronic HE may occur in up to 25 percent of patients [<a href="#rid11">11-16</a>]. For example, in patients with variceal bleeding, the risk of HE was higher after TIPS insertion compared with endoscopic therapy. In a meta-analysis of 12 trials including 883 patients with variceal bleeding, patients with TIPS were more likely to develop HE compared with endoscopic sclerotherapy (odds ratio [OR] 2.21, 95% CI 1.61-3.03) [<a href="#rid14">14</a>]. Shunting of portal venous blood through the liver limits the metabolic filtering process of the liver parenchyma, and this contributes to new or worsening HE for patients after TIPS [<a href="#rid1">1</a>].</p><p>Risk factors for post-TIPS HE include:</p><p class="bulletIndent1"><span class="glyph">●</span>Hyponatremia [<a href="#rid17">17</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Sarcopenia [<a href="#rid18">18</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Older age [<a href="#rid11">11</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Prior history of HE [<a href="#rid11">11,12</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Larger shunt diameter (eg, &gt;10 mm) [<a href="#rid19">19,20</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Alcohol-associated cirrhosis [<a href="#rid16">16</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Covert HE or cognitive impairment on testing [<a href="#rid11">11,12</a>]</p><p></p><p>According to Poiseuille's equation, resistance to flow can be defined as:</p><div class="formulaContainer"><div class="formula"><p>  Resistance = 8nl ÷ πr(4)</p></div></div><p>Where r is the radius of the stent, n is the coefficient of viscosity, and l is the length of the vessel. Thus, the resistance to flow through the shunt decreases exponentially with increasing shunt diameter, resulting in increases in shunt flow and portosystemic shunting. As a result, the risk of HE would be expected to increase with larger shunt diameters. However, one trial that assigned 45 patients to receive either 8 or 10 mm diameter stents failed to show an increased incidence of HE in patients with larger diameter stents [<a href="#rid20">20</a>]. At one year, the probability of being free of HE was not significantly different in patients with an 8 mm stent compared with a 10 mm stent. In addition, the trial was stopped early because of a higher portosystemic pressure gradient in patients who received the 8 mm stent (8.9 versus 6.5 mmHg). This correlated with a lower rate of having no complications related to portal hypertension in patients with smaller shunts (42 versus 83 percent).</p><p class="headingAnchor" id="H4024172223"><span class="h4">Clinical presentation</span><span class="headingEndMark"> — </span>HE usually becomes clinically apparent two to three weeks after TIPS insertion [<a href="#rid21">21,22</a>], while the occurrence of HE ≥6 weeks after TIPS insertion is typically precipitated by gastrointestinal bleeding. Additional precipitating factors for and symptoms of HE are similar to those that occur in patients with cirrhosis but without TIPS (eg, altered sleep pattern, confusion, disorientation), and these are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1237.html" rel="external">"Hepatic encephalopathy in adults: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H2209292962"><span class="h4">Prevention</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10202" href="/z/d/drug information/10202.html" rel="external">Rifaximin</a> prophylaxis may be reasonable for patients with risk factors for post-TIPS HE (eg, sarcopenia, older patient age, alcohol-associated cirrhosis). (See <a class="local">'Incidence and etiology'</a> above.)</p><p>However, we do not routinely use pharmacologic prophylaxis for preventing post-TIPS HE because data on the benefits of prophylaxis have been mixed [<a href="#rid16">16,23-25</a>]. In a trial including 197 patients with alcohol-associated cirrhosis who were scheduled for TIPS placement and were followed for six months, <a class="drug drug_general" data-topicid="10202" href="/z/d/drug information/10202.html" rel="external">rifaximin</a> prophylaxis resulted in lower rates of post-TIPS HE compared with no prophylaxis (34 versus 53 percent; OR 0.48, 95% CI 0.27-0.87) [<a href="#rid16">16</a>]. Rates of other liver disease-related complications (eg, bleeding) were not significantly different between the groups. In an earlier trial of 75 patients with cirrhosis who had TIPS placement, rates of post-TIPS HE were not significantly different for patients given prophylaxis with rifaximin or lactitol compared with no prophylaxis [<a href="#rid24">24</a>]. Additional trials are needed to determine if rifaximin is beneficial for preventing post-TIPS encephalopathy in most patients, while balancing the potential barriers to its use (eg, duration of therapy, cost).</p><p class="headingAnchor" id="H518671971"><span class="h4">Treatment</span><span class="headingEndMark"> — </span>Treatment of post-TIPS encephalopathy is similar to that of HE in other settings. When HE develops <em>de novo</em> or worsens after TIPS insertion, the patient is evaluated for precipitating factors (eg, gastrointestinal bleeding, dehydration, infection), and these coexisting conditions are treated when possible. (See  <a class="medical medical_review" href="/z/d/html/1237.html" rel="external">"Hepatic encephalopathy in adults: Clinical manifestations and diagnosis", section on 'Evaluation for precipitating causes'</a>.)</p><p>Initial medical management of HE typically includes <a class="drug drug_general" data-topicid="9543" href="/z/d/drug information/9543.html" rel="external">lactulose</a>, along with nutritional support. The management of HE, including the approach to patients who do not respond to initial therapy, is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1255.html" rel="external">"Hepatic encephalopathy in adults: Treatment"</a>.)</p><p>For patients with TIPS and HE that is refractory to medical therapy, options also include revising the shunt to reduce the diameter or occluding the shunt, although this approach reverses the benefits of the procedure [<a href="#rid26">26,27</a>]. While consensus is lacking, reducing shunt diameter is generally an option for patients who have ≥3 HE episodes that were not precipitated by other factors and that required hospital admission [<a href="#rid28">28</a>].</p><p>In one series, an attempt was made to quantify and follow the severity of encephalopathy after TIPS using a PSE index [<a href="#rid21">21</a>]. The PSE index rose sharply within 7 to 10 days after TIPS placement  (<a class="graphic graphic_figure graphicRef72160" href="/z/d/graphic/72160.html" rel="external">figure 1</a>). Over time, the PSE index declined, but at six months, it remained higher compared with baseline values and values in concurrent matched controls who underwent sclerotherapy. The decline in PSE index may be attributed to both treatment of HE and the development of stent stenosis, due to pseudointimal hyperplasia, which reduced the degree of portosystemic shunting. Subsequent studies using cognitive tests have demonstrated declining performance on these tests following TIPS, especially in selected patients (eg, those with sarcopenia or pre-TIPS cognitive impairment) [<a href="#rid11">11,12</a>]. Patients may also undergo such testing prior to TIPS placement to assess risk for post-TIPS HE. (See <a class="local">'Incidence and etiology'</a> above.)</p><p class="headingAnchor" id="H141506782"><span class="h3">Cardiac failure</span><span class="headingEndMark"> — </span>Cardiac decompensation and/or failure is a complication of TIPS and results from a large-volume blood shift from the splanchnic circulation to the systemic circulation, increasing venous return to the heart, cardiac output, and right heart pressures [<a href="#rid29">29</a>]. In some patients, this increased venous return acts as a volume challenge and can unmask a previously undiagnosed cirrhotic cardiomyopathy or worsen portopulmonary hypertension [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/4943.html" rel="external">"Definition and classification of the cardiomyopathies", section on 'Cirrhotic cardiomyopathy'</a> and  <a class="medical medical_review" href="/z/d/html/8266.html" rel="external">"Portopulmonary hypertension"</a>.)</p><p>However, despite initial volume overload, cardiovascular stabilization occurs during the first several months for most patients after TIPS placement, and specialty consultation (eg, cardiology, pulmonary) is obtained to help guide management [<a href="#rid31">31,32</a>].</p><p>The approach to pre-TIPS cardiac evaluation is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1265.html" rel="external">"Overview of transjugular intrahepatic portosystemic shunts (TIPS)", section on 'Pre-TIPS evaluation and planning'</a>.)</p><p>Pre-TIPS cardiac evaluation may help to identify patients at risk for cardiac decompensation after TIPS insertion. In a cohort study including 100 patients with cirrhosis (primarily alcohol-related disease), 20 patients (20 percent) developed cardiac decompensation requiring hospitalization after a median follow-up of 316 days. Risk factors for cardiac decompensation included aortic stenosis, diastolic dysfunction based on echocardiography, prolonged QTc interval, and elevated pre-TIPS brain natriuretic peptide (BNP) and N-terminal pro-BNP [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/3486.html" rel="external">"Natriuretic peptide measurement in heart failure"</a>.)</p><p class="headingAnchor" id="H4135961300"><span class="h2">Liver failure</span><span class="headingEndMark"> — </span>Liver failure after TIPS insertion has been defined as ≥3-fold increase in total bilirubin and/or ≥2-fold international normalized ratio elevation that is associated with need for further intervention (eg, liver transplantation) or worse outcome (ie, mortality). The reported incidence of post-TIPS liver failure is 20 percent [<a href="#rid14">14,34</a>]. Pre-TIPS risk factors for liver failure include high Model for End-stage Liver Disease (MELD) score (ie, MELD &gt;20) and underlying cardiovascular disease. (See  <a class="medical medical_review" href="/z/d/html/1241.html" rel="external">"Model for End-stage Liver Disease (MELD)"</a>.)</p><p>Precipitants of acute liver failure after TIPS include:</p><p class="bulletIndent1"><span class="glyph">●</span>Sepsis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal bleeding.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Iatrogenic liver injury.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inability to increase arterial blood flow to the hepatic sinusoids (eg, reduced cardiac contractility) [<a href="#rid35">35</a>]. Hepatic arterial blood flow is often increased after creation of a portosystemic shunt, and patients who cannot increase arterial flow after diverting portal venous flow through the shunt may be predisposed to liver failure. The management of liver failure includes supportive care and treating reversible factors (eg, infection). For patients who do not respond to these measures and who are unlikely to have hepatic recovery, liver transplantation is the only viable option for long-term survival. (See  <a class="medical medical_review" href="/z/d/html/3570.html" rel="external">"Acute liver failure in adults: Management and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H4166027862"><span class="h2">Infection</span><span class="headingEndMark"> — </span>Infections involving TIPS are uncommon and include endovascular shunt infection and periprocedural sepsis, and they are managed with intravenous antibiotics [<a href="#rid36">36-38</a>]. Selecting antibiotic therapy in this setting is similar to other intra-abdominal infections, and this is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/101694.html" rel="external">"Antimicrobial approach to intra-abdominal infections in adults", section on 'Empiric antimicrobial therapy'</a>.)</p><p>Bacteremia (or fungemia) associated with endovascular TIPS infection (referred to as endotipsitis) is a rare complication but may occur after TIPS insertion or revision [<a href="#rid38">38-41</a>]. Sources of most infections include the gastrointestinal tract and skin, and endotipsitis was associated with a high mortality rate. In a review of case reports and small case series including 56 patients with infected TIPS, the mortality rate for patients with bacteremia with an infected TIPS was 32 percent (18 out of 56 patients) [<a href="#rid38">38</a>].</p><p>Preprocedure preparation including antibiotic prophylaxis is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1265.html" rel="external">"Overview of transjugular intrahepatic portosystemic shunts (TIPS)", section on 'Pre-TIPS evaluation and planning'</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">TIPS dysfunction</span><span class="headingEndMark"> — </span>TIPS dysfunction is defined as a loss of decompression of the portal venous system due to occlusion or stenosis of the TIPS. Patients with TIPS dysfunction typically present with symptoms of recurrent portal hypertension (eg, ascites, variceal bleeding). If TIPS dysfunction is suspected, liver ultrasound with Doppler study is performed to evaluate for stent narrowing or occlusion.</p><p>Causes of TIPS dysfunction include [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Thrombosis – Extensive thrombosis of the TIPS, portal vein, or splenic vein has been reported in up to 12 percent of patients after TIPS insertion. However, the available data reflect the era of bare metal stents, while the thrombosis risk with covered stents is uncertain [<a href="#rid6">6,42-45</a>]. In addition, no specific risk factors for thrombosis have been identified [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/3579.html" rel="external">"Acute portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p class="bulletIndent1">Pharmacologic prophylaxis with anticoagulation is not required after TIPS insertion for maintaining shunt patency.</p><p></p><p class="bulletIndent1">If thrombosis does occur, patients typically present within the first month after TIPS. Treatment options include thrombolysis, anticoagulation, or suction thrombectomy [<a href="#rid46">46</a>]. In those who are transplant candidates, liver transplantation is definitive treatment. We have used both suction thrombectomy followed by urgent liver transplant and thrombolysis followed by long-term anticoagulation in this setting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stenosis or occlusion – Data have suggested that use of polytetrafluoroethylene (PTFE)-covered stents reduced the risk of shunt stenosis [<a href="#rid47">47-49</a>]. In a trial of 258 patients with cirrhosis who underwent TIPS placement, use of PTFE-covered stents resulted in lower risk of shunt dysfunction (defined as &gt;50 percent reduction in shunt lumen or by portosystemic pressure gradient &gt;12 mmHg) after five years compared with bare metal stents (risk ratio [RR] 0.42, 95% CI 0.28-0.61) [<a href="#rid48">48,49</a>]. In an earlier trial of 80 patients who underwent TIPS placement followed by Doppler ultrasound every three months for two years, rates of TIPS patency were higher in patients with covered stents compared with bare metal stents (76 versus 36 percent) [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1">TIPS stenosis or occlusion is caused by pseudointimal hyperplasia within the parenchymal tract or within the outflow hepatic vein. The occluded stent is coated with a collagenous matrix, covered by endothelial cells [<a href="#rid50">50,51</a>].</p><p></p><p><strong>Other complications</strong> — TIPS is very rarely associated with hemolytic anemia in the setting of stents covered with PTFE (rather than bare metal stents) [<a href="#rid2">2,52</a>]. TIPS-associated hemolytic anemia is defined as new onset hemolysis with or without anemia in the absence of alternate causes (eg, spur cell anemia). (See  <a class="medical medical_review" href="/z/d/html/7168.html" rel="external">"Non-immune (Coombs-negative) hemolytic anemias in adults"</a>.)</p><p>When TIPS-associated hemolysis occurs, it typically presents within 7 to 14 days after stent placement with an increase in serum bilirubin that is mostly unconjugated [<a href="#rid2">2,53</a>]. This is accompanied by reticulocytosis and a decrease in serum haptoglobin. Whether overt anemia develops depends upon the balance between red cell production and destruction. Most patients have a mild (&lt;2 g/dL) reduction in hemoglobin concentration, but severe anemia with high-output heart failure can occur. The diagnosis of hemolytic anemia is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">"Diagnosis of hemolytic anemia in adults"</a>.)</p><p>The typical course of TIPS-associated hemolysis for most patients is spontaneous resolution within 8 to 12 weeks; however, the mechanism for recovery is unclear [<a href="#rid2">2</a>]. It may reflect covering of the metal wires with endothelium and smoothing the edges of the parenchymal tract, thereby reducing shear stress. Severe hemolysis rarely persists beyond 12 weeks, although one case report suggests that orthotopic liver transplantation was required for refractory hemolytic anemia [<a href="#rid52">52</a>].</p><p>Hemolysis may result from injury to red cells from shear stress or direct mechanical trauma in the shunt with culling of abnormal cells in the spleen [<a href="#rid2">2,53</a>].</p><p class="headingAnchor" id="H137229795"><span class="h1">PROGNOSIS</span></p><p class="headingAnchor" id="H2098512477"><span class="h2">Survival</span><span class="headingEndMark"> — </span>Mortality rates directly related to TIPS insertion have ranged from 0 to 2 percent [<a href="#rid42">42</a>], while overall mortality (measured at 30 days in most studies) ranged from approximately 5 to 50 percent [<a href="#rid42">42,54-58</a>].</p><p>Factors associated with higher mortality risk included [<a href="#rid57">57,58</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Child-Pugh C class cirrhosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemodynamic instability and/or active bleeding at the time of TIPS insertion</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urgent procedure (ie, acute variceal bleeding)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated serum bilirubin level (eg, &gt;3 mg/dL)</p><p></p><p>Mortality after TIPS was usually related to underlying liver disease and liver failure, multiorgan failure, and/or sepsis [<a href="#rid1">1,59</a>].</p><p>However, TIPS was not associated with a higher mortality rate than other treatments for variceal bleeding. In a meta-analysis of 12 trials including 883 patients with variceal bleeding, there were no significant differences in mortality rates for patients treated with TIPS compared with endoscopic sclerotherapy (25 versus 22 percent) [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H368192972"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114698.html" rel="external">"Society guideline links: Portal hypertension and ascites"</a>.)</p><p class="headingAnchor" id="H70135472"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background</strong> – Transjugular intrahepatic portosystemic shunt (TIPS) is an important therapeutic tool for patients with complications of portal hypertension (eg, variceal bleeding, refractory ascites). TIPS insertion reduces elevated portal pressure by creating a low-resistance channel between the hepatic vein and an intrahepatic branch of the portal vein  (<a class="graphic graphic_figure graphicRef72311" href="/z/d/graphic/72311.html" rel="external">figure 2</a>). The tract is kept patent by deployment of a stent across it, thereby allowing blood to return to the systemic circulation. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postprocedure care</strong> – For patients who undergo TIPS insertion, initial postprocedure care consists of observation for signs/symptoms of complications (eg, bleeding, cardiac dysfunction) and laboratory studies (eg, complete blood count, international normalized ratio, liver biochemical and function tests). Imaging (liver ultrasound with Doppler study) is typically performed in three to seven days after the procedure. (See <a class="local">'Initial postprocedure care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-TIPS surveillance</strong> – For patients with TIPS, we perform surveillance imaging to assess shunt patency. Liver ultrasound with Doppler study is performed between three and six months after TIPS insertion and then at six-month intervals for long-term surveillance.</p><p></p><p class="bulletIndent1">The goal of surveillance is to detect TIPS stenosis before recurrent symptoms develop (eg, ascites, variceal bleeding). (See <a class="local">'Post-TIPS surveillance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Issues related to portosystemic shunting</strong> – Hepatic encephalopathy (HE) is a complication of TIPS due to shunting of blood from the portal to systemic circulation. The incidence of HE following TIPS ranges from 30 to 50 percent. (See <a class="local">'Incidence and etiology'</a> above.)</p><p></p><p class="bulletIndent1">For most patients who undergo TIPS placement, we suggest no pharmacologic prophylaxis of post-TIPS HE (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, <a class="drug drug_general" data-topicid="10202" href="/z/d/drug information/10202.html" rel="external">rifaximin</a> prophylaxis may be reasonable for patients with risk factors for post-TIPS HE (eg, sarcopenia, older age, alcohol-associated cirrhosis). (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="bulletIndent1">Cardiac decompensation and/or failure is a complication of TIPS and results from a large-volume blood shift from the splanchnic circulation to the systemic circulation, increasing venous return to the heart, cardiac output, and right heart pressures. In some patients, this increased venous return acts as a volume challenge and can unmask a previously undiagnosed cirrhotic cardiomyopathy or worsen portopulmonary hypertension. (See <a class="local">'Cardiac failure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TIPS dysfunction</strong> – Patients with TIPS dysfunction or occlusion typically present with symptoms of recurrent portal hypertension (eg, ascites, variceal bleeding). If TIPS dysfunction is suspected, liver ultrasound with Doppler study is performed to evaluate for stent narrowing or occlusion. (See <a class="local">'TIPS dysfunction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Mortality rates directly related to TIPS insertion have ranged from 0 to 2 percent. Overall mortality (measured at 30 days in most studies) for patients after TIPS ranged from approximately 5 to 50 percent and was usually related to liver failure, multiorgan failure, and/or sepsis. (See <a class="local">'Survival'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Loffroy R, Favelier S, Pottecher P, et al. Transjugular intrahepatic portosystemic shunt for acute variceal gastrointestinal bleeding: Indications, techniques and outcomes. Diagn Interv Imaging 2015; 96:745.</a></li><li><a class="nounderline abstract_t">Sanyal AJ, Freedman AM, Purdum PP, et al. The hematologic consequences of transjugular intrahepatic portosystemic shunts. Hepatology 1996; 23:32.</a></li><li><a class="nounderline abstract_t">Carr CE, Tuite CM, Soulen MC, et al. Role of ultrasound surveillance of transjugular intrahepatic portosystemic shunts in the covered stent era. J Vasc Interv Radiol 2006; 17:1297.</a></li><li><a class="nounderline abstract_t">Engstrom BI, Horvath JJ, Suhocki PV, et al. Covered transjugular intrahepatic portosystemic shunts: accuracy of ultrasound in detecting shunt malfunction. AJR Am J Roentgenol 2013; 200:904.</a></li><li><a class="nounderline abstract_t">Sanyal AJ, Genning C, Reddy KR, et al. The North American Study for the Treatment of Refractory Ascites. Gastroenterology 2003; 124:634.</a></li><li><a class="nounderline abstract_t">Sanyal AJ, Freedman AM, Luketic VA, et al. The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology 1997; 112:889.</a></li><li><a class="nounderline abstract_t">Darcy M. Evaluation and management of transjugular intrahepatic portosystemic shunts. AJR Am J Roentgenol 2012; 199:730.</a></li><li><a class="nounderline abstract_t">Kim SK, Belikoff BG, Guevara CJ, Park SJ. An Algorithm for Management After Transjugular Intrahepatic Portosystemic Shunt Placement According to Clinical Manifestations. Dig Dis Sci 2017; 62:305.</a></li><li><a class="nounderline abstract_t">Feldstein VA, Patel MD, LaBerge JM. Transjugular intrahepatic portosystemic shunts: accuracy of Doppler US in determination of patency and detection of stenoses. Radiology 1996; 201:141.</a></li><li><a class="nounderline abstract_t">Kanterman RY, Darcy MD, Middleton WD, et al. Doppler sonography findings associated with transjugular intrahepatic portosystemic shunt malfunction. AJR Am J Roentgenol 1997; 168:467.</a></li><li><a class="nounderline abstract_t">Nardelli S, Gioia S, Pasquale C, et al. Cognitive Impairment Predicts The Occurrence Of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt. Am J Gastroenterol 2016; 111:523.</a></li><li><a class="nounderline abstract_t">Berlioux P, Robic MA, Poirson H, et al. Pre-transjugular intrahepatic portosystemic shunts (TIPS) prediction of post-TIPS overt hepatic encephalopathy: the critical flicker frequency is more accurate than psychometric tests. Hepatology 2014; 59:622.</a></li><li><a class="nounderline abstract_t">Fonio P, Discalzi A, Calandri M, et al. Incidence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS) according to its severity and temporal grading classification. Radiol Med 2017; 122:713.</a></li><li><a class="nounderline abstract_t">Zheng M, Chen Y, Bai J, et al. Transjugular intrahepatic portosystemic shunt versus endoscopic therapy in the secondary prophylaxis of variceal rebleeding in cirrhotic patients: meta-analysis update. J Clin Gastroenterol 2008; 42:507.</a></li><li><a class="nounderline abstract_t">Zhu Y, Wang X, Xi X, et al. Emergency Transjugular Intrahepatic Portosystemic Shunt: an Effective and Safe Treatment for Uncontrolled Variceal Bleeding. J Gastrointest Surg 2019; 23:2193.</a></li><li><a class="nounderline abstract_t">Bureau C, Thabut D, Jezequel C, et al. The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial. Ann Intern Med 2021; 174:633.</a></li><li><a class="nounderline abstract_t">Merola J, Chaudhary N, Qian M, et al. Hyponatremia: A Risk Factor for Early Overt Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation. J Clin Med 2014; 3:359.</a></li><li><a class="nounderline abstract_t">Nardelli S, Lattanzi B, Torrisi S, et al. Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement. Clin Gastroenterol Hepatol 2017; 15:934.</a></li><li><a class="nounderline abstract_t">Riggio O, Angeloni S, Salvatori FM, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol 2008; 103:2738.</a></li><li><a class="nounderline abstract_t">Riggio O, Ridola L, Angeloni S, et al. Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: results of a randomized controlled trial. J Hepatol 2010; 53:267.</a></li><li><a class="nounderline abstract_t">Sanyal AJ, Freedman AM, Shiffman ML, et al. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. Hepatology 1994; 20:46.</a></li><li><a class="nounderline abstract_t">Riggio O, Merlli M, Pedretti G, et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors. Dig Dis Sci 1996; 41:578.</a></li><li><a class="nounderline abstract_t">Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014; 60:715.</a></li><li><a class="nounderline abstract_t">Riggio O, Masini A, Efrati C, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol 2005; 42:674.</a></li><li><a class="nounderline abstract_t">Neff G, Zachry W III. Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin. Pharmacoeconomics 2018; 36:809.</a></li><li><a class="nounderline abstract_t">Kerlan RK Jr, LaBerge JM, Baker EL, et al. Successful reversal of hepatic encephalopathy with intentional occlusion of transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol 1995; 6:917.</a></li><li><a class="nounderline abstract_t">Hauenstein KH, Haag K, Ochs A, et al. The reducing stent: treatment for transjugular intrahepatic portosystemic shunt-induced refractory hepatic encephalopathy and liver failure. Radiology 1995; 194:175.</a></li><li><a class="nounderline abstract_t">Boike JR, Thornburg BG, Asrani SK, et al. North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension. Clin Gastroenterol Hepatol 2022; 20:1636.</a></li><li><a class="nounderline abstract_t">Filì D, Falletta C, Luca A, et al. Circulatory response to volume expansion and transjugular intrahepatic portosystemic shunt in refractory ascites: Relationship with diastolic dysfunction. Dig Liver Dis 2015; 47:1052.</a></li><li><a class="nounderline abstract_t">Colombato L. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension. J Clin Gastroenterol 2007; 41:S344.</a></li><li><a class="nounderline abstract_t">Huonker M, Schumacher YO, Ochs A, et al. Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut 1999; 44:743.</a></li><li><a class="nounderline abstract_t">Merli M, Valeriano V, Funaro S, et al. Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am J Gastroenterol 2002; 97:142.</a></li><li><a class="nounderline abstract_t">Billey C, Billet S, Robic MA, et al. A Prospective Study Identifying Predictive Factors of Cardiac Decompensation After Transjugular Intrahepatic Portosystemic Shunt: The Toulouse Algorithm. Hepatology 2019; 70:1928.</a></li><li><a class="nounderline abstract_t">Gaba RC, Lakhoo J. What constitutes liver failure after transjugular intrahepatic portosystemic shunt creation? A proposed definition and grading system. Ann Hepatol 2016; 15:230.</a></li><li><a class="nounderline abstract_t">Jansen C, Schröder A, Schueler R, et al. Left Ventricular Longitudinal Contractility Predicts Acute-on-Chronic Liver Failure Development and Mortality After Transjugular Intrahepatic Portosystemic Shunt. Hepatol Commun 2019; 3:340.</a></li><li><a class="nounderline abstract_t">Sanyal AJ, Reddy KR. Vegetative infection of transjugular intrahepatic portosystemic shunts. Gastroenterology 1998; 115:110.</a></li><li><a class="nounderline abstract_t">Venkatesan AM, Kundu S, Sacks D, et al. Practice guidelines for adult antibiotic prophylaxis during vascular and interventional radiology procedures. Written by the Standards of Practice Committee for the Society of Interventional Radiology and Endorsed by the Cardiovascular Interventional Radiological Society of Europe and Canadian Interventional Radiology Association [corrected]. J Vasc Interv Radiol 2010; 21:1611.</a></li><li><a class="nounderline abstract_t">Garcia-Zamalloa A, Gomez JT, Egusquiza AC. New Case of Endotipsitis: Urgent Need for Clinical Practice Guidelines. Eurasian J Med 2017; 49:214.</a></li><li><a class="nounderline abstract_t">McCarty TR, Sack J, Syed B, et al. Fungal endotipsitis: A case report and literature review. J Dig Dis 2017; 18:237.</a></li><li><a class="nounderline abstract_t">Jessani LG, Nayak S, Lingam P, et al. Endotipsitis caused by extremely drug-resistant Klebsiella pneumoniae. Trop Gastroenterol 2015; 36:280.</a></li><li><a class="nounderline abstract_t">Navaratnam AM, Grant M, Banach DB. Endotipsitis: A case report with a literature review on an emerging prosthetic related infection. World J Hepatol 2015; 7:710.</a></li><li><a class="nounderline abstract_t">Freedman AM, Sanyal AJ, Tisnado J, et al. Complications of transjugular intrahepatic portosystemic shunt: a comprehensive review. Radiographics 1993; 13:1185.</a></li><li><a class="nounderline abstract_t">Lind CD, Malisch TW, Chong WK, et al. Incidence of shunt occlusion or stenosis following transjugular intrahepatic portosystemic shunt placement. Gastroenterology 1994; 106:1277.</a></li><li><a class="nounderline abstract_t">Theilmann L, Sauer P, Roeren T, et al. Acetylsalicylic acid in the prevention of early stenosis and occlusion of transjugular intrahepatic portal-systemic stent shunts: a controlled study. Hepatology 1994; 20:592.</a></li><li><a class="nounderline abstract_t">Sauer P, Theilmann L, Herrmann S, et al. Phenprocoumon for prevention of shunt occlusion after transjugular intrahepatic portosystemic stent shunt: a randomized trial. Hepatology 1996; 24:1433.</a></li><li><a class="nounderline abstract_t">Raat H, Stockx L, Ranschaert E, et al. Percutaneous hydrodynamic thrombectomy of acute thrombosis in transjugular intrahepatic portosystemic shunt (TIPS): a feasibility study in five patients. Cardiovasc Intervent Radiol 1997; 20:180.</a></li><li><a class="nounderline abstract_t">Bureau C, Garcia Pagan JC, Layrargues GP, et al. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study. Liver Int 2007; 27:742.</a></li><li><a class="nounderline abstract_t">Wang L, Xiao Z, Yue Z, et al. Efficacy of covered and bare stent in TIPS for cirrhotic portal hypertension: A single-center randomized trial. Sci Rep 2016; 6:21011.</a></li><li><a class="nounderline abstract_t">Zhu P, Dong S, Sun P, et al. Expanded polytetrafluoroethylene (ePTFE)-covered stents versus bare stents for transjugular intrahepatic portosystemic shunt in people with liver cirrhosis. Cochrane Database Syst Rev 2023; 8:CD012358.</a></li><li><a class="nounderline abstract_t">Saxon RR, Mendel-Hartvig J, Corless CL, et al. Bile duct injury as a major cause of stenosis and occlusion in transjugular intrahepatic portosystemic shunts: comparative histopathologic analysis in humans and swine. J Vasc Interv Radiol 1996; 7:487.</a></li><li><a class="nounderline abstract_t">Ducoin H, El-Khoury J, Rousseau H, et al. Histopathologic analysis of transjugular intrahepatic portosystemic shunts. Hepatology 1997; 25:1064.</a></li><li><a class="nounderline abstract_t">Sanyal AJ, Freedman AM, Purdum PP III. TIPS-associated hemolysis and encephalopathy. Ann Intern Med 1992; 117:443.</a></li><li><a class="nounderline abstract_t">Conn HO. Hemolysis after transjugular intrahepatic portosystemic shunting: the naked stent syndrome. Hepatology 1996; 23:177.</a></li><li><a class="nounderline abstract_t">LaBerge JM, Ring EJ, Gordon RL, et al. Creation of transjugular intrahepatic portosystemic shunts with the wallstent endoprosthesis: results in 100 patients. Radiology 1993; 187:413.</a></li><li><a class="nounderline abstract_t">Rössle M, Haag K, Ochs A, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 1994; 330:165.</a></li><li><a class="nounderline abstract_t">Sanyal AJ, Freedman AM, Luketic VA, et al. Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy. Gastroenterology 1996; 111:138.</a></li><li><a class="nounderline abstract_t">Rajan DK, Haskal ZJ, Clark TW. Serum bilirubin and early mortality after transjugular intrahepatic portosystemic shunts: results of a multivariate analysis. J Vasc Interv Radiol 2002; 13:155.</a></li><li><a class="nounderline abstract_t">Helton WS, Belshaw A, Althaus S, et al. Critical appraisal of the angiographic portacaval shunt (TIPS). Am J Surg 1993; 165:566.</a></li><li><a class="nounderline abstract_t">Chau TN, Patch D, Chan YW, et al. "Salvage" transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding. Gastroenterology 1998; 114:981.</a></li></ol></div><div id="topicVersionRevision">Topic 1251 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26094039" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Transjugular intrahepatic portosystemic shunt for acute variceal gastrointestinal bleeding: Indications, techniques and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8550045" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The hematologic consequences of transjugular intrahepatic portosystemic shunts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16923976" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Role of ultrasound surveillance of transjugular intrahepatic portosystemic shunts in the covered stent era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23521468" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Covered transjugular intrahepatic portosystemic shunts: accuracy of ultrasound in detecting shunt malfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12612902" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The North American Study for the Treatment of Refractory Ascites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9041251" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22997362" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Evaluation and management of transjugular intrahepatic portosystemic shunts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28058594" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : An Algorithm for Management After Transjugular Intrahepatic Portosystemic Shunt Placement According to Clinical Manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8816535" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Transjugular intrahepatic portosystemic shunts: accuracy of Doppler US in determination of patency and detection of stenoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9016228" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Doppler sonography findings associated with transjugular intrahepatic portosystemic shunt malfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26925879" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cognitive Impairment Predicts The Occurrence Of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24620380" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pre-transjugular intrahepatic portosystemic shunts (TIPS) prediction of post-TIPS overt hepatic encephalopathy: the critical flicker frequency is more accurate than psychometric tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28510807" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Incidence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS) according to its severity and temporal grading classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18344888" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Transjugular intrahepatic portosystemic shunt versus endoscopic therapy in the secondary prophylaxis of variceal rebleeding in cirrhotic patients: meta-analysis update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30790218" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Emergency Transjugular Intrahepatic Portosystemic Shunt: an Effective and Safe Treatment for Uncontrolled Variceal Bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33524293" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26237379" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Hyponatremia: A Risk Factor for Early Overt Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27816756" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18775022" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20537753" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: results of a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8020904" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8617139" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25042402" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15826716" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29651649" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8850669" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Successful reversal of hepatic encephalopathy with intentional occlusion of transjugular intrahepatic portosystemic shunts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7997547" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The reducing stent: treatment for transjugular intrahepatic portosystemic shunt-induced refractory hepatic encephalopathy and liver failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34274511" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26427586" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Circulatory response to volume expansion and transjugular intrahepatic portosystemic shunt in refractory ascites: Relationship with diastolic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17975487" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10205217" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11808939" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31512743" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A Prospective Study Identifying Predictive Factors of Cardiac Decompensation After Transjugular Intrahepatic Portosystemic Shunt: The Toulouse Algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31196405" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : What constitutes liver failure after transjugular intrahepatic portosystemic shunt creation? A proposed definition and grading system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30984902" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Left Ventricular Longitudinal Contractility Predicts Acute-on-Chronic Liver Failure Development and Mortality After Transjugular Intrahepatic Portosystemic Shunt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9649465" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Vegetative infection of transjugular intrahepatic portosystemic shunts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21029949" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Practice guidelines for adult antibiotic prophylaxis during vascular and interventional radiology procedures. Written by the Standards of Practice Committee for the Society of Interventional Radiology and Endorsed by the Cardiovascular Interventional Radiological Society of Europe and Canadian Interventional Radiology Association [corrected].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29123448" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : New Case of Endotipsitis: Urgent Need for Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28127943" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Fungal endotipsitis: A case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27509714" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Endotipsitis caused by extremely drug-resistant Klebsiella pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25866608" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Endotipsitis: A case report with a literature review on an emerging prosthetic related infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8290720" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Complications of transjugular intrahepatic portosystemic shunt: a comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8174889" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Incidence of shunt occlusion or stenosis following transjugular intrahepatic portosystemic shunt placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8076917" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Acetylsalicylic acid in the prevention of early stenosis and occlusion of transjugular intrahepatic portal-systemic stent shunts: a controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8938176" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Phenprocoumon for prevention of shunt occlusion after transjugular intrahepatic portosystemic stent shunt: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9134840" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Percutaneous hydrodynamic thrombectomy of acute thrombosis in transjugular intrahepatic portosystemic shunt (TIPS): a feasibility study in five patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17617116" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26876503" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Efficacy of covered and bare stent in TIPS for cirrhotic portal hypertension: A single-center randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37531575" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Expanded polytetrafluoroethylene (ePTFE)-covered stents versus bare stents for transjugular intrahepatic portosystemic shunt in people with liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8855524" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Bile duct injury as a major cause of stenosis and occlusion in transjugular intrahepatic portosystemic shunts: comparative histopathologic analysis in humans and swine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9141418" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Histopathologic analysis of transjugular intrahepatic portosystemic shunts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1503342" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : TIPS-associated hemolysis and encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8550038" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Hemolysis after transjugular intrahepatic portosystemic shunting: the naked stent syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8475283" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Creation of transjugular intrahepatic portosystemic shunts with the wallstent endoprosthesis: results in 100 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8264738" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8698192" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11830621" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Serum bilirubin and early mortality after transjugular intrahepatic portosystemic shunts: results of a multivariate analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8488938" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Critical appraisal of the angiographic portacaval shunt (TIPS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9558287" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : "Salvage" transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
